Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
News|Articles|May 31, 2024
Psychedelics Beyond Clinical Settings Poll
Author(s)Psychiatric Times Editors
Answer a quick question on psychedelics!
Advertisement
Have your patients shared or expressed interest in psychedelics for therapeutic purposes outside of clinical settings?
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
Adjustment Disorder Is Hiding in Plain Sight
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5